30
CARDIOVASCULAR
hamburger
Xience Prime™ BTK Everolimus Eluting Peripheral Stent System

The Next Step in BTK Efficacy.

XIENCE Prime BTK Everolimus Eluting Peripheral Stent System is clinically proven for primary stenting of focal and long lesions and is engineered for outstanding performance.1,2

Advancing BTK efficacy

Clinically Proven

  • Excellent long-term patency (angiographic binary in-stent restenosis (>50% stenosis)) of 85.2% and 98.7% limb salvage at 1 year.3,4

Xience Prime BTK Pre-procedure
Pre-procedure4
Xience Prime BTK Post-procedure
Post-procedure4
Xience Prime BTK 12 Months Post-procedure
12 months post-procedure4
Advancing BTK Efficacy

Engineered for outstanding performance

  • Leading MULTI-LINK stent design for exceptional acute performance, uncompromised radial force, and visibility5
  • Coating technology for reliable expansion and controlled Everolimus drug release
  • Innovative delivery system for excellent deliverability and confident deployment
Xience Prime BTK Engineering

ORDERING INFORMATION

XIENCE Prime™ BTK Peripheral Stent System
Stock Number
Stent Diameter (mm) Stent Length (mm) Nominal Pressure (atm)
RBP (atm) Max Stent Expansion Diameter (mm)
1012646-28 2.5 28 8 18 3.25
1012646-38 2.5 38 8 18 3.25
1012648-28 3.0 28 10 18 3.75
1012648-38 3.0 38 10 18 3.75
1012649-28 3.5 28 10 18 4.5
1012649-38 3.5 38 10 18 4.5
1012650-28 4.0 28 10 18 4.5
1012650-38 4.0 38 10 18 4.5

References

  1. Bosiers, M et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease; J Vascular Surgery 2012;55:390-399.
  2. Bosier, M et al.Outcome of a drug eluted stent in longer below the knee lesions in patients with critical limb ischemia: J Vascular Surgery 2017;58(1):49-54
  3. M. Bosiers, DESTINY, VEITH 2010
  4. M. Bosiers, LINC 2011
  5. Tests and data on file at Abbott

MAT-2115185 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.